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Aim We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in patients who have cor-
onary artery disease (CAD), with insulin resistance (IR) and/or pre-diabetes.
...................................................................................................................................................................................................
Methods
and results
We randomly assigned 68 patients (mean age 65 ± 8 years) without diabetes who have CAD with IR and/or pre-
diabetes to receive either metformin XL (2000 mg daily dose) or placebo for 12 months. Primary endpoint was
change in left ventricular mass indexed to height1.7 (LVMI), assessed by magnetic resonance imaging. In the modified
intention-to-treat analysis (n= 63), metformin treatment significantly reduced LVMI compared with placebo group
(absolute mean difference -1.37 (95% confidence interval: -2.63 to -0.12, P= 0.033). Metformin also significantly
reduced other secondary study endpoints such as: LVM (P= 0.032), body weight (P= 0.001), subcutaneous adipose
tissue (P= 0.024), office systolic blood pressure (BP, P= 0.022) and concentration of thiobarbituric acid reactive
substances, a biomarker for oxidative stress (P= 0.04). The glycated haemoglobin A1C concentration and fasting IR
index did not differ between study groups at the end of the study.
...................................................................................................................................................................................................
Conclusion Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress.
Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-
protective role of metformin is required from large CV outcomes trials.
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Introduction
Left ventricular hypertrophy (LVH) is an independent predictor of
mortality and is highly prevalent in patients with ischaemic heart
disease, even in the absence of hypertension.1,2 Left ventricular
hypertrophy is a common finding in approximately one-third of
patients with coronary artery disease (CAD).3 Importantly, LVH is
one of the most powerful prognostic factor in CAD, after age and
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coronary disease severity with a prognostic importance equivalent to
that of left ventricular (LV) ejection fraction.3,4 Regression of LVH
can reduce the incidence of major cardiovascular (CV) events irre-
spective of blood pressure (BP) changes.5–7 However, controlling BP
is only partially effective as LVH persists in 20% of hypertensive
patients who attain target BP.8 Therefore, additional strategies are
required.
Other than BP, insulin resistance (IR) and central obesity are impli-
cated in the development of LVH. Dysglycaemia is very common in
patients with CAD and is linked to IR.9 Large studies have reported a
significant positive relationship between IR and LVH.10–12 Specifically,
central obesity has been associated with IR, hypertension, and LVH.13
Importantly, non-diabetic dysglycaemia (pre-diabetes) per se is associ-
ated with substantial CV risk that is now recognized by clinical prac-
tice guidelines.14
Metformin—an anti-diabetic drug, has been shown to improve in-
sulin sensitivity and reduce IR.15 In a meta-analysis of randomized
controlled trials (RCTs), Salpeter et al.16 reported a reduction of
weight and calculated IR in metformin users. Metformin has multiple
modes of actions involving both AMP-activated protein kinase
(AMPK)-dependent and AMPK-independent mechanisms that may
be implicated in cardiac hypertrophy.17 In this respect, metformin has
been shown to reduce cardiac hypertrophy in different animal mod-
els of hypertrophy.18 Observational studies have also reported CV
benefits in metformin users19 especially in patients with type 2 dia-
betes mellitus (T2DM) and heart failure.20 For these reasons, there is
now much interest in the repurposing of metformin for CV
diseases.21
In this ‘proof of concept’ RCT, we hypothesized that metformin
would cause regression of LVH in patients without T2DM, with CAD
and dysglycaemia identified by IR and/or pre-diabetes.
Methods
Study design
The MET-REMODEL study (NCT02226510) was a single centre, double-
blind, placebo-controlled trial designed to evaluate the efficacy of a 12-
month Metformin XL (prolonged release) 1000 mg twice daily treatment
on LVH in non-diabetic, participants identified to have CAD, LVH, and IR
and/or pre-diabetes. Figure 1 shows the MET-REMODEL trial consort
type flow diagram and Supplementary material online, Figure S1 shows
the study design. The study was approved by the East of Scotland
Research Ethical Committee (14/ES/1061 IRAS) and all patients provided
written informed consent.
Study participants
The study population included 68 patients recruited between April 2015
and September 2016 from Tayside, Scotland, using research databases,
hospital records, and local general practices. Participating patients were
aged 18–85 years with documented CAD (previous myocardial infarc-
tion/unstable angina and/or previous revascularization by either percutan-
eous coronary intervention or coronary artery bypass graft surgery) and
without diabetes (ascertained by clinical history extracted from medical
notes and screening HbA1c measurement of >_ 48 mmol/mol). Patients
were also required to have IR [IR defined using fasting insulin resistance
index (FIRI >_2.7) measured by an empirical FIRI, consisting of the product
of plasma insulin and glucose: FIRI = fasting glucose  fasting insulin/25]
AND/OR American Diabetes Association defined pre-diabetes: glycated
haemoglobin (HbA1c) >_39 mmol/mol and <48 mmol/mol.22,23 Patients
with hypertension were not excluded from the study but their prevailing
BP had to be in the normotensive range with a clinic BP <_140/85 mmHg
(mean value of three measurements performed at 5 min intervals on
same arm). Detailed study exclusion criteria are described in Section A in
the Supplementary material online. Presence of LVH was based on pub-
lished sex specific normal values of LV mass allometrically scaled to height
(LV mass/height1.7 >95th percentile) ascertained by screening echocardi-
ography (males >81 g/h1.7, females >60 g/h1.7).24 Given the high preva-
lence of obesity (BMI >_ 30 kg/m2) in these study patients, we determined
LVMI by LVM/height1.7, which has been shown to be a sensitive method
to assess LVMI.24
Participants who met the eligibility criteria were randomly assigned to
receive either metformin XL 500 mg twice daily or matching placebo in a
double-blind fashion (randomization protocol described in Section B in
the Supplementary material online) for 2 weeks. If this was tolerated, the
dosage was increased to 1000 mg twice daily for a further 11 months. If
the higher dose could not be tolerated, it was reduced to 1000 mg/day,
or stopped altogether if this lower dosage was not tolerated.
Magnetic resonance imaging
Images at baseline and at 12 months were acquired on a 3.0T Tesla mag-
netic resonance imaging (MRI) scanner (Magnetom Trio-PrismaFIT,
Siemens, Erlangen, Germany) using spine matrix and body array matrix
RF coils. The cardiac MRI (CMR) and abdominal MRI protocols used are
described in Section C in the Supplementary material online.
Flow-mediated dilatation
Endothelial function was assessed using a Sequoia 512 (Siemens,
Camberley, England) ultrasound machine with an 8 MHz linear array
probe to measure flow-mediated dilatation (FMD) of the brachial artery
in response to hyperaemia at baseline visit and at 12 months, according to
the standard guidelines as described by Coretti et al.25
Laboratory investigations
Routine biochemical and haematological investigations were measured at
all study visits as safety parameters. Fasting plasma glucose, HbA1c, fasting
insulin, biomarkers of interest such as interleukin-6 (IL-6), Soluble ST2,
N-terminal pro-brain natriuretic peptide (NTproBNP) and thiobarbituric
acid reactive substances (TBARs) were measured at baseline and final
visit.
Vital signs (office BP, heart rate, and weight) were assessed at every
study visit. Adverse events (AEs) and serious adverse events (SAEs) were
patient reported.
Study endpoints
The primary endpoint was to determine whether metformin induces re-
gression of LVMI assessed by CMR. The secondary endpoints were
changes in LV ejection fraction, mass, and volumes; abdominal obesity
assessed by MRI, glycaemic parameters, endothelial function, and blood
biomarkers.
Power calculation
The sample size was based on changes in LVM, using published data from
a previous LVH regression study with CMR (5 g change, SD 2.8) in a simi-
lar cohort of patients.26 For an 80% power at a 5% significance level
(a= 0.05), to detect a similar change in LVM, we will require 29 subjects
per group in our study. We enrolled 34 patients per group to allow a
15% drop out rate.
2 M. Mohan et al.
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Statistical analysis
The primary outcome comparison was based on modified intention-to-
treat (mITT) analysis, i.e. all participants who had baseline measurements
and took at least one dose of investigational medicinal product were ana-
lysed as part of the group to which they were randomized. Missing post-
baseline values were imputed using the baseline observation carried for-
ward (BCOF—all the variables for two patients in the placebo arm) ap-
proach. However, to provide a true estimate of the efficacy of
intervention, a per-protocol analysis was also performed. The comparison
between intervention and placebo groups was compared using independ-
ent samples t-tests for continuous variables and v2 for dichotomous varia-
bles. Continuous variables with normal distribution are presented as mean
(SD). Non-normally distributed data were presented as medians alongside
their inter-quartile ranges. They subsequently underwent log transform-
ation to achieve normality. Additionally, we performed a sensitivity analysis
using analysis of covariance (ANCOVA) model to evaluate the robustness
of treatment with change in LVMI, LVM and treatment as fixed effects, and
age, sex, and baseline values for LVMI/LMI, body weight, systolic blood
pressure (SBP), diastolic blood pressure (DBP), prescription of angioten-
sin-converting enzyme inhibitor, angiotensin II receptor blockers, and
beta-blocker as covariates. A P-value <0.05 was considered significant.
Data were analysed using SPSS 22.0 (IBM Corp, Armonk, NY, USA).
Results
Recruitment and follow-up
Of the 187 participants who were screened, 68 subjects (Figure 1) ful-
filled all the study criteria and were randomly allocated to receive
either metformin (N= 34) or placebo (N= 34). Five patients were
excluded from all study analysis prior to unblinding: no baseline MRI
measurements due to claustrophobia (N= 1); comorbidity—inciden-
tal finding of abdominal aortic aneurysm on MRI that required imme-
diate medical attention prior to starting on study drug (N= 1),
withdrawn consent (N= 1) and protocol breach (N= 2; co-
enrolment). Seven patients discontinued study medications: prema-
ture treatment discontinuation due to AEs (N= 5); lost to follow-up
(N= 1) and pre-existing comorbidity (N= 1) however, they were
included in our mITT analysis. Sixty-three patients in total completed
the study (N= 31 in metformin group; N= 32 in placebo group) as
per the study protocol and were included for analysis in the mITT
arm of the study and 56 patients (N= 27 in metformin group; N= 29
in placebo group) in the per-protocol population.
Patient characteristics
Baseline characteristics of study population at randomization are
shown in Table 1. When compared with the placebo group, patients
in the metformin group had somewhat higher fasting IR index, abso-
lute LV mass measurements, weighed more, had more frequent posi-
tive exercise tolerance testing and use of calcium-channel blockers,
although these differences were not statistically significant.
Primary outcome
In the mITT analysis, metformin treatment significantly reduced LVMI
(change in LVMI: metformin group -2.71± 2.31 g/m1.7 vs. placebo
Figure 1 Trial consort diagram.
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Table 1 Baseline characteristics of study population
Variable All patients
(n5 63)
Metformin
(n5 31)
Placebo
(n5 32)
P-value
Demographics
Age, in years 64.6 ± 8.4 64.5 ± 8.9 64.6 ± 8.0 0.971
Sex (% of males) 47 (75) 26 (84) 21 (66) 0.096
Ex-smokers (%) 3 (5) 16 (52) 17 (53) 0.993
Current smokers (%) 8 (13) 4 (13) 4 (13)
Alcohol consumption (%) 41 (65) 19 (61) 22 (69) 0.430
Weight, kg 90.3 ± 12.9 93.3 ± 12.9 87.3 ± 12.3 0.074
Body mass index, kg/m2 32.0 ± 3.5 32.2 ± 3.4 31.9 ± 3.6 0.419
Systolic blood pressure, mmHg 130.6 ± 10.9 130.8 ± 10.7 130.5 ± 11.2 0.903
Diastolic blood pressure, mmHg 75.8 ± 7.9 75.3 ± 8.0 76.4 ± 7.9 0.591
Pre-diabetes (%) 50 (79) 23(74) 27(84) 0.326
Insulin resistant (%) 44(70) 25(81) 19(59) 0.096
Pre-diabetes þ insulin resistance (%) 32 (51) 17 (55) 15 (47) 0.535
Heart rate, b.p.m. 57.7± 9.1 57.6 ± 9.9 57.8 ± 8.4 0.953
MRI study assessments
Absolute LVM, g 114.8 ± 24.8 120.7 ± 20.3 109.1 ± 27.6 0.064
LVMI (height1.7) 47.3 ± 8.1 48.7 ± 6.5 46.0 ± 9.3 0.197
Subcutaneous adipose tissue, cm3 3332.7 ± 1044.1 3371.6 ± 1037.0 3301.6 ± 1090.3 0.897
Visceral adipose tissue, cm3 2422.6 ± 878.5 2407.1 ± 881.7 2441.8 ± 892.2 0.713
Flow-mediated dilatation
Response to hyperaemia (%) 5.3 ± 2.3 5.4 ± 2.4 5.1 ± 2.1 0.690
Response to GTN (%) 14.8 ± 5.4 15.2 ± 4.8 14.3 ± 6 0.540
Past medical history
Myocardial infarction (%) 32 (51) 15 (48) 17 (53) 0.803
Elective PCI (%) 15 (24) 5 (16) 10 (31) 0.237
Positive ETT in those without angiogram/previous MI (%) 11 (18) 7 (23) 4 (13) 0.337
CABG (%) 8 (13) 5 (16) 3 (9) 0.421
Hypertension (%) 31 (49) 15 (48) 16 (50) 0.898
Dyslipidaemia (%) 58 (92) 28 (90) 30 (94) 0.615
Medication
ACE inhibitors (%) 44 (70) 24 (77) 20 (63) 0.197
ARB (%) 11 (18) 4 (13) 7 (22) 0.348
Beta-blockers (%) 51 (81) 24 (77) 27 (84) 0.482
Calcium-channel blocker (%) 14 (22) 9 (29) 5 (16) 0.508
Statins (%) 57 (91) 30 (97) 27 (84) 0.094
Anti-platelet drugs (%) 62 (98) 30 (97) 32 (100) 0.306
Laboratory measurements
Creatinine, lmol/L 76.2 ±14.0 78.3 ± 12.1 73.4 ± 15.1 0.504
Urea, mmol/L 5.9 ± 1.2 5.9 ± 0.9 5.7 ± 1.2 0.743
eGFR, mL/min, MDRD 91.7 ± 17.6 92.0 ± 14.8 91.0 ± 20.3 0.580
Fasting insulin, mU/L 17.8 ±10.0 19.5 ± 9.6 15.2 ± 10.0 0.220
Fasting glucose, mmol/L 5.5 ± 0.6 5.5 ± 0.5 5.4 ± 0.5 0.856
FIRI 3.8 ± 2.1 4.2 ± 2.0 3.3 ± 2.2 0.263
HbA1c, mmol/mol 40.2 ± 2.5 39.9 ± 2.6 40.5 ± 2.5 0.279
NTproBNP, pg/mL (median IQR) 877.2 (1166.4) 957.8 (1029.1) 796.5 (1247.0) 0.490
IL-6 pg/mL (median IQR) 0.6 (0.39) 0.6 (0.4) 0.6 (0.4) 0.980
Soluble ST2, ng/mL (median IQR) 18.1 (11.3) 17.2 (11.5) 18.9 (11.9) 0.440
TBARs, mM 3.0 ±1.2 2.9 ±1.5 3.1 ±1.2 0.520
Values are mean ± SD, n (%), or median (IQR).
ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; ETT, exercise tolerance test; eGFR, esti-
mated glomerular filtration rate; FIRI, fasting insulin resistance index; GTN, glyceryl trinitrate; HbA1c, glycated haemoglobin; IL-6, interleukin-6; IQR, inter-quartile range; LVM,
left ventricular mass; LVMI, left ventricular mass index; MI, myocardial Infarction; MDRD, modification of diet in renal disease; MRI, magnetic resonance imaging; NTproBNP,
N-terminal pro B-type natriuretic peptide; PCI, percutaneous coronary intervention; TBARs, thiobarbituric acid reactive substances.
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..group -1.34 ± 2.65 g/m1.7; P= 0.033), leading to an absolute mean dif-
ference of -1.37 (95% confidence interval: -2.63 to -0.12). The reduc-
tion on LVMI was even greater in the per-protocol population
(change in LVMI: metformin group -3.12 ± 1.95 g/m1.7 vs. placebo
group -1.29 ± 2.67 g/m1.7; P= 0.005) (Table 2 and Figure 2). Additional
sensitivity analysis for the mITT and per-protocol population con-
ducted using a one-way ANCOVA to compare the effectiveness of
treatment, adjusting for relevant confounders showed that the
change in LVMI observed in metformin group was higher compared
with placebo: (i) for mITT arm—estimated marginal means: metfor-
min group -2.8 g/m1.7 [95% confidence interval, -3.8 to -1.9] vs. pla-
cebo group -1.2 g/m1.7 [95% confidence interval, -2.1 to -0.3] and (ii)
per-protocol population—estimated marginal means: metformin
group -3.3 g/m1.7 [95% confidence interval, -4.2 to -2.3] vs. placebo
group -1.2 g/m1.7 [95% confidence interval, -2.1 to -0.23] and
remained statistically significant (P= 0.019 for mITT and P= 0.004 for
per-protocol analysis), suggesting that this finding was robust and not
driven by potential relevant baseline characteristics.
Secondary outcomes
There were no significant differences between treatment groups at
12 months for other cardiac secondary endpoints such as LVEF,
LVEDV, LVESV, and LVSV except for LVM (Supplementary material
online, Table S1). Metformin treatment significantly reduced LVM
(change in LVM: metformin group -6.53 ± 5.59 g vs. placebo group
-3.23± 6.32 g; P= 0.032) in the mITT analysis, leading to an absolute
mean difference of -3.3 (95% confidence interval: -6.32 to -0.29)
(Table 2 and Figure 2). The treatment effect on LVM was greater
when analysed using the per-protocol population with a highly signifi-
cant reduction in LVM (change in LVM: metformin group
-7.53± 4.66 g vs. placebo group -3.13± 6.36 g; P= 0.005).
Abdominal MRI images were obtained from 61 patients but 13
patients were excluded from this analysis due to inadequate image
quality. Hence, 48 (26 and 22 in metformin arm and placebo arm, re-
spectively) and 44 (23 and 21 in metformin arm and placebo arm, re-
spectively) patients were included in the mITT arm and per-protocol
population analysis, respectively. Subcutaneous and visceral abdomin-
al tissue (SCAT and VAT) areas were quantified and there was no
statistically significant difference between treatment groups at base-
line. Treatment with metformin significantly reduced SCAT (mITT: %
change in SCAT: metformin group -6.74± 11.19 vs. placebo group
-0.27 ± 7.21; P= 0.024; per-protocol: metformin group -8.84 ± 10 vs.
placebo group -0.28 ± 7.39; P= 0.003) (Table 2) whereas metformin
treatment did not have a significant effect on VAT (Supplementary
material online, Table S1).
We did not observe any effect of metformin treatment on FMD in
both mITT and per-protocol analysis (Supplementary material online,
Table S1).
No significant differences were identified in changes in concentra-
tion of NTproBNP, soluble ST2 and IL-6 (Supplementary material
online, Table S1). However, metformin treatment significantly
reduced the concentration of TBARs; a by-product of lipid peroxida-
tion and a marker of oxidative stress (change in TBARs: metformin
group -0.26± 1.04 mM vs. placebo group 0.33 ± 1.14 mM; P= 0.04) in
the mITT analysis (Table 2).
At baseline, patients in the metformin group had a slightly higher
level of FIRI and fasting insulin. There was no significant metformin
treatment induced changes in glycaemic parameters such as fasting
plasma glucose, fasting insulin, HbA1c, or FIRI but there was a statis-
tically significant reduction in fasting glucose (P= 0.009) when ana-
lysed in the per-protocol population (Supplementary material online,
Table S1).
Effect of metformin on office blood pressure and weight
Compared with placebo, metformin treatment resulted in a signifi-
cant reduction of body weight and SBP in the mITT and per-protocol
analysis arm of the study (Table 2 and Supplementary material online,
Figure S2). These findings on office SBP and weight reduction were
corroborated by a subgroup analysis, which showed that reduction
of office SBP, and body weight was progressive over the entire dur-
ation of study (Supplementary material online, Figure S3). No correl-
ation was observed between change in LVM and change in body
.......................................................................................... ........................................................................................
....................................................................................................................................................................................................................
Table 2 Changes after 12 months of metformin treatment
Outcomes Modified intention—to—treat analysis Per-protocol analysis
Metformin Placebo Differencea (95% CI) P-value Metformin Placebo Differencea (95% CI) P-value
Primary outcome
LVMI, g/m1.7 -2.71 ± 2.31 -1.34 ± 2.66 -1.37 (-2.63 to -0.12) 0.033 -3.12 ± 1.95 -1.29 ± 2.67 -1.83 (-3.1 to -0.57) 0.005
Key secondary outcomes
LVM, g -6.53 ± 5.59 -3.23 ± 6.32 -3.3 (-6.32 to -0.29) 0.032 -7.53 ± 4.66 -3.13 ± 6.36 -4.4 (-7.4 to -1.4) 0.005
SCAT, % - 6.74 ± 11.19 -0.27 ± 7.21 -6.47 (-12.06 to -0.89) 0.024 -8.84 ± 10.0 -0.28 ± 7.39 -8.56 (-13.95 to -3.16) 0.003
Body weight, Kgs -3.61 ± 4.88 -0.01 ± 3.63 -3.6 (-5.77 to -1.44) 0.001 -4.22 ± 4.9 -0.04 ± 3.81 -4.18 (-6.52 to -1.83) 0.001
TBARs, mM -0.26 ± 1.04 0.33 ± 1.14 -0.59 (-1.16 to -0.03) 0.040 -0.32 ± 1.1 0.36 ± 1.15 -0.68 (-1.29 to -0.07) 0.030
Other outcomes
SBP, mmHg -4.81 ± 15.57 4.31 ± 15.26 -9.12 (-16.89 to -1.35) 0.022 -4.56 ± 15.82 4.28 ± 15.9 -8.83 (-17.34 to -0.33) 0.042
P-values in bold indicate P< 0.05.
aAbsolute mean difference between groups. All values expressed in mean ± SD unless stated.
LVM, left ventricular mass; LVMI, left ventricular mass index; SBP, systolic blood pressure; SCAT, subcutaneous adipose tissue; TBARs, thiobarbituric acid reactive substances.
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weight and SBP [Pearson correlation, r (61) = 0.07, P= 0.569 for
change in LVM and change in BP; Pearson correlation, r (61) = 0.21,
P= 0.105 for change in LVM and change in body weight].
Tolerability and safety of metformin
Study medication was generally well tolerated with no reported cases
of lactic acidosis or renal impairment during follow-up. There were
34 AEs and 11 SAEs recorded for the study cohort; 19 AEs and 6
SAEs in the metformin group (N= 31); and 15 AEs and 4 SAEs in the
placebo group (N= 32). Majority of patients in the metformin group
experienced gastrointestinal disorders (diarrhoea = 47%; flatulence
=26%; abdominal discomfort = 5%) compared with placebo group.
Although majority of these AEs were transient and were mild to
moderate in severity, study medication was prematurely terminated
for five patients (metformin group = 4, due to severe diarrhoea or
abdominal discomfort; placebo group = 1, developed T2DM). Dose
was reduced to 1 g daily for four patients in the metformin group due
to diarrhoea or abdominal discomfort at the higher dose. The mean
tolerable dose of metformin was 1610 mg per day in this study.
There were no reported CV (myocardial infarction, arrhythmias,
stroke, and heart failure) SAEs in the placebo arm, but one participant
in the metformin group had a stroke.
Discussion
The main finding of our study is that a modified-release 2000 mg daily
dose of metformin treatment significantly reduced LVMI in patients
without T2DM who have CAD, LVH and IR and/or pre-diabetes
who were optimally treated with evidence-based therapy. The re-
gression of LVH observed in this study was independent of changes
in IR. We also found that metformin reduced measures of obesity,
reduced SBP and oxidative stress compared with placebo. All these
findings were consistent in both mITT and per-protocol analysis, sug-
gesting a robust beneficial cardio-protective effect of metformin in
this group of patients.
The CV benefits of metformin has largely been underpinned by
the United Kingdom Prospective Diabetes Study (UKPDS) that
reported lower CV mortality and morbidity in patients treated with
metformin.27 However, recent meta-analysis suggests that the CV
effects of metformin could be smaller than that reported by UKPDS;
however, this should be interpreted with caution as there has only
Figure 2 Effect of metformin ton left ventricular mass index and left ventricular mass. (A) This graph illustrates the effect of 12 months of metfor-
min or placebo treatment on the left ventricular mass index. Metformin significantly reduced left ventricular mass index after 12 months of therapy
compared with placebo (P = 0.033 for modified intention-to-treat and P = 0.005 for per-protocol analysis). (B) This graph illustrates the effect of 12
months of metformin or placebo treatment on the left ventricular mass. Metformin significantly reduced left ventricular mass after 12 months of ther-
apy compared with placebo (P = 0.032 for modified intention-to-treat and P = 0.005 for per-protocol analysis.
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..been a small number of RCTs.28 While patients with cardiovascular
disease (CVD) with T2DM comorbidity are likely to benefit most
from metformin, indications of CV benefit over other diabetes treat-
ments has driven interest in repurposing metformin to treat CVD, ir-
respective of diabetes status.21
To the best of our knowledge, this is the first RCT investigating the
effect of metformin on LVH in non-diabetic CAD patients identified
to have IR and/or pre-diabetes. Our findings are consistent with ex-
perimental animal studies showing that metformin can regress
LVH.18 With regards to clinical studies, a small (n= 40), open-
labelled, echocardiographic study reported that 6 months treatment
with metformin reduced LVM and relative wall thickness in non-
diabetic subjects with metabolic syndrome.29 Furthermore, in an
echocardiographic sub-study of the GIPS III trial, metformin treat-
ment for 4 months was associated with a marginal, but non-significant
reduction of LVMI in non-diabetic subjects who have had a myocar-
dial infarction.30 Conversely, a recent network meta-analysis based
on only three metformin trials reported minimal beneficial effects of
metformin on LVM in subjects with T2DM.31 Taking all this together,
the data would suggest that metformin might be able to regress LVH.
Left ventricular hypertrophy is regarded as one of the strongest in-
dependent predictors of CV outcome and the LIFE study had conclu-
sively shown that LVH regression per se reduces future CV events
irrespective of BP changes.32,33 However, it remains to be proven on
whether metformin-induced LVH regression can deliver the same
magnitude of reduction in CV events as the LIFE study since the mag-
nitude of LVH regression was greater in the LIFE study when patients
received treatment for at least 4 years.6 We believe that a CV out-
come trial of metformin among subjects without T2DM is needed to
change clinical practice. In this regard, the CV benefits of metformin
are currently being tested in the VA IMPACT trial (https://clinical
trials.gov/ct2/show/NCT02915198), an outcome trial involving close
to 8000 patients similarly identified as in MET-REMODEL to have
pre-diabetes and established atherosclerotic CV disease including
CAD.
There are plausible mechanisms for why metformin produced
LVH regression in our study (Take home figure). Firstly, metformin
could mediate LVH regression through its effect on BP. A recent
pooled meta-analysis of RCTs of metformin on BP in patients without
T2DM reported that metformin can significantly lower SBP, especially
in patients with impaired glucose tolerance or obesity (BMI >_ 30 kg/
m2), with a mean reduction of 5 and 3 mmHg, respectively.34 The
magnitude of BP reduction was similar in our study with a reduction
of SBP (4.6 mmHg) in metformin group. A second plausible mechan-
ism for LVH regression may be metformin induced reduction in body
weight. In our study, metformin therapy reduced body weight by ap-
proximately 4 kg and reduced MRI measured SCAT by 8.8%. Our
results are in keeping with the findings of the CAMERA study involv-
ing non-diabetic individuals, where metformin significantly reduced all
measures of adiposity (body weight, body fat, BMI, waist, circumfer-
ence) in non-diabetic patients with CAD, with a mean weight loss of
3.2 kg in metformin group.35–37 In our study, we only observed a sig-
nificant effect of metformin on SCAT and not on VAT. The effect of
metformin on VAT in non-diabetic individuals has not been studied
before. In T2DM patients, metformin has been reported to reduce
VAT although this is not a consistent finding.38,39 Hence, more stud-
ies are needed to investigate the impact of metformin therapy on ab-
dominal obesity, especially on endogenous fat depots. Thirdly,
Take home ﬁgure Plausible mechanisms by which metformin regressed left ventricular mass index.
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oxidative stress has been pathophysiologically linked to LVH and in
our study, metformin reduced oxidative stress as observed by the re-
duction of TBARs, a biomarker of oxidative stress.40–42 Our findings
are in keeping with the study by Esteghamati et al.43 that reported
that metformin is more effective in reducing oxidative stress com-
pared with lifestyle modification alone. Fourthly, metformin could
mediate this through its insulin-sensitizing properties.16 Insulin
resistance is thought to contribute to changes in cardiac tissue seen
in LVH.44 In this study, metformin treatment reduced fasting blood
glucose but only resulted in non-significant marginal reductions in
FIRI and HbA1c. Previous studies on metformin in non-diabetic indi-
viduals also reported none or modest effects on HbA1c.35,45 We did
not find any changes to vascular function (FMD) in this group of
patients. It is noteworthy that the effect of metformin on endothelial
function as assessed by FMD has not been consistent.41,46 Finally, as
suggested by previous studies with animal models of LVH,18 it is
plausible that activation of AMPK by metformin could have played a
role in the regression of LVH. It is worth noting that other mecha-
nisms such as increasing nitric oxide bioavailability, limiting interstitial
fibrosis, reducing the deposition of advanced glycation end-products,
and inhibiting myocardial cell apoptosis have also been proposed for
metformin’s efficacy in reducing cardiac remodelling and hyper-
trophy.47 However, this remains purely speculative and cannot be
directly inferred from this clinical study.
Limitations of the study
Firstly, this is a single centre study with relatively small number of
patients. However, this trial is the largest prospective, adequately
powered RCT conducted to date, investigating the efficacy of metfor-
min to regress LVH. Secondly, the study was statistically powered
only for a single outcome and not statistically powered to detect
changes in other study secondary endpoints. Therefore, inferential
between group comparisons for these secondary endpoints are likely
to be exploratory rather than definitive. Thirdly, our study was lim-
ited to those with CAD and does not address LVH in those without
CAD. Fourthly, in this study, we only used one biomarker to measure
oxidative stress. We recognize the importance to use more than one
criterion to evaluate oxidative stress, as there may be methodological
bias associated with different biomarkers for oxidative stress.48
Nevertheless, TBARs has been shown as a promising biomarker with
prognostic implications, particularly in patients with CAD.42 Fifthly,
our patient cohort with dysglycaemia have either IR or pre-diabetes
or both. We recognize that IR and pre-diabetes may represent differ-
ent sub-set of populations of patients. Importantly, there was no dif-
ference in the proportion of these dysglycaemic states between the
two groups. Finally, because of the relatively small sample size, we
cannot exclude the possibility that some subtle baseline and demo-
graphic differences between the two groups, although not statistically
different, might have collectively contributed to our results.
Conclusion and future directions
In conclusion, this study has shown, for the first time in a RCT that
metformin treatment significantly reduced LVMI and LVM compared
with placebo in patients with CAD without T2DM. It also improved
SBP, reduced oxidative stress and reduced measures of obesity such
as body weight and SCAT. Although LVH is a good surrogate marker
of CV outcome, we believe that a CV outcome trial of metformin is
needed to provide definitive evidence for the cardio-protective role
of metformin in non-diabetic CV disease. The results of ongoing CV
outcome trials such as the VA IMPACT trial (VA IMPACT
NCT02915198) and Glucose Lowering in Non-diabetic hypergly-
caemia Trial (GLINT; ISRCTN34875079), will be informative and
help provide the needed evidence for recommending metformin in
these at risk patients.
Supplementary material
Supplementary material is available at European Heart Journal online.
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